Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects

NCT04439929 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

168

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Participants

Interventions

BIOLOGICAL: TUR01
BIOLOGICAL: Adalimumab-EU

Sponsor

Turgut İlaçları A.Ş.